Loading cancer entity…
Loading cancer entity…
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 |
| NCT04417660 | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05104736 | PT-112 in Subjects With Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01025089 | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03134118 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)(NIVOTHYM) | active not recruiting | Phase 2 | 55 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 15, 2026 | clinicaltrials |
| NCT04710628 | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents(PECATI) | completed | Phase 2 | 43 | MedSIROTHER | 3 | Feb 19, 2026 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06186726 | Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06730308 | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01621568 | Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)(Artemis) | recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT00010257 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00003283 | Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy(SELECT) | terminated | Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02049047 | Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy(ONC-2010-001) | completed | Phase 2 | 41 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04371458 | Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT05407649 | Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours | unknown | Phase 2 | 60 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02220855 | A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas | completed | Phase 2 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03663764 | Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT00198133 | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | completed | Phase 2 | 27 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01364727 | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | completed | Phase 2 | 33 | Heather WakeleeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01301391 | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | terminated | Phase 2 | 30 | Tiziana Life Sciences LTDINDUSTRY | 2 | Feb 6, 2019 | clinicaltrials |
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma(TET-SEL) | unknown | Phase 2 | 25 | Morten Mau-SoerensenOTHER | 2 | Mar 15, 2018 | clinicaltrials |
| NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | terminated | Phase 1 / Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00332969 | Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00589290 | Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00718809 | Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00387868 | Preoperative Treatment of Patients With High Risk Thymoma | completed | Phase 2 | 21 | Valley Health SystemOTHER | 2 | Dec 9, 2014 | clinicaltrials |
| NCT00369889 | A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer | completed | Phase 2 | 18 | Indiana UniversityOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00818090 | Paclitaxel and Cisplatin for Thymic Neoplasm | terminated | Phase 2 | 39 | Korean Cancer Study GroupOTHER | 1 | Apr 12, 2013 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials